drugset
drugset / Trial / NCT05228496

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

NCT05228496 ↗

Phase 2 Unknown 21 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with sitravatinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve extensive stage small cell lung cancer.

Timeline

Start
2022-03-17
Primary completion
2023-07-21
Completion
2025-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitravatinib Small molecule 100 mg Oral
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

small cell lung carcinoma